rabbit polyclonal antihuman cd3 antibody (Agilent technologies)
Agilent technologies is a verified supplier 
Agilent technologies manufactures this product 
90
Structured Review
Agilent technologies
rabbit polyclonal antihuman cd3 antibody
Rabbit Polyclonal Antihuman Cd3 Antibody, supplied by Agilent technologies, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rabbit polyclonal antihuman cd3 antibody/product/Agilent technologies
Average 90 stars, based on 1 article reviews
Rabbit Polyclonal Antihuman Cd3 Antibody, supplied by Agilent technologies, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rabbit polyclonal antihuman cd3 antibody/product/Agilent technologies
Average 90 stars, based on 1 article reviews
rabbit polyclonal antihuman cd3 antibody - by Bioz Stars,
2026-03
90/100 stars
Images
1) Product Images from "Impact of Preanalytical Factors During Histology Processing on Section Suitability for Digital Image Analysis"
Article Title: Impact of Preanalytical Factors During Histology Processing on Section Suitability for Digital Image Analysis
Journal: Toxicologic Pathology
doi: 10.1177/0192623320970534
Figure Legend Snippet: Reagents for IHC Staining.
Techniques Used: Staining, Concentration Assay, Incubation
Figure Legend Snippet: The staining intensity of a particular IHC method is influenced more by the biomarker than the choice of stainer. Data are shown as the CV (calculated as the SD divided by the mean) for the average OD within each staining run for each biomarker on a given instrument for all tissues. The box plots represent the distribution of the data, where the box defines the range encompassing values between the 25th and 75th quartiles, the line within the box is drawn at the median OD, and the whiskers demonstrate the expected variation in the data. Dots located over some boxes (eg, CD3 on instrument 0083) plot data that fell beyond the whiskers, which are indicative of staining runs with higher than expected variability. For Ki-67, the expanded ranges (longer boxes) on all 3 stainers denote that staining was more variable across runs for sections containing lymphoid tissue (see ). Instrument models: AutostainerPlus Link, Nos. 0010 and 0083; Autostainer Link 48, No. 0151. CV indicates coefficient of variation; DAB, 3,3′-diaminobenzidene; IHC, immunohistochemical; OD, optical density; SD, standard deviation.
Techniques Used: Staining, Biomarker Assay, Immunohistochemical staining, Standard Deviation
![Staining intensity may be impacted unexpectedly by inadvertent adjustments to the IHC protocol design. In this example, Ki-67-positive cells in 4-µm-thick step sections exhibit stronger staining when processed using a protocol in which the incubation in primary antibody is followed rapidly by application of the visualization reagent (ie, the standard protocol [column A]) relative to 4-µm thick step sections in which the primary antibody was followed by a 35-min incubation in buffer before addition of the visualization reagent (column B); the extended buffer incubation for Ki-67 corresponded to the time needed to accommodate another biomarker in the same staining run (CD45, which requires incubation with a secondary antibody prior to application of the visualization reagent). The decreased staining intensity associated with extended rinsing for some staining runs likely explains the higher variation in Ki-67 labeling across instruments (see ) relative to labeling provided by the other biomarkers tested in this study (CD3, CD45, F4/80). IHC indicates immunohistochemical.](https://pub-med-central-images-cdn.bioz.com/pub_med_central_ids_ending_with_1422/pmc08091422/pmc08091422__10.1177_0192623320970534-fig12.jpg "... by the other biomarkers tested in this study (CD3, CD45, F4/80). IHC indicates immunohistochemical.")
Figure Legend Snippet: Staining intensity may be impacted unexpectedly by inadvertent adjustments to the IHC protocol design. In this example, Ki-67-positive cells in 4-µm-thick step sections exhibit stronger staining when processed using a protocol in which the incubation in primary antibody is followed rapidly by application of the visualization reagent (ie, the standard protocol [column A]) relative to 4-µm thick step sections in which the primary antibody was followed by a 35-min incubation in buffer before addition of the visualization reagent (column B); the extended buffer incubation for Ki-67 corresponded to the time needed to accommodate another biomarker in the same staining run (CD45, which requires incubation with a secondary antibody prior to application of the visualization reagent). The decreased staining intensity associated with extended rinsing for some staining runs likely explains the higher variation in Ki-67 labeling across instruments (see ) relative to labeling provided by the other biomarkers tested in this study (CD3, CD45, F4/80). IHC indicates immunohistochemical.
Techniques Used: Staining, Incubation, Biomarker Assay, Labeling, Immunohistochemical staining